Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 17:47:58 +0200Fri, 12 Jul 2024 16:10:00 +0200Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 6, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/imjudoHuman medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 6, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/imjudoFri, 12 Jul 2024 16:10:00 +0200Human medicineImjudo : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-6016_en_2.pdfImjudo : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-6016_en_2.pdfFri, 12 Jul 2024 15:37:00 +0200Human medicine